FDA Approves Another Chemotherapy Assay, First Monoclonal Her-2/neu Test
This article was originally published in The Gray Sheet
Executive Summary
BioGenex's February launch of its InSite Her-2/neu monoclonal antibody kit for breast cancer detection will be supported by 12 U.S. sales reps